secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2026-05-12T12:10:23+00:00
Accession:  0001213900-26-054744
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q2 product revenue up 72% to $2.4M; net loss narrows to $2.1M
----------------------------------------------------------------------

- Product revenue $2.4M (+72% YoY); no license revenue vs $3.0M in prior year first half.
- Net loss $2.1M ($0.25/sh) vs $2.3M ($0.44/sh) in same quarter last year.
- Cash $2.8M; working capital $5.7M; no debt outstanding; accounts receivable $2.4M.
- 16 trigeminal neuralgia cases completed with all patients reportedly pain free.
- Christopher Volker to become CFO effective July 1, 2026; David Wambeke hired as CBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026054744/0001213900-26-054744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026054744/ea0290094-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer